Current Grant Opportunities
The Lymphoma Research Foundation announces Request for Proposals on a regular basis each year. In calendar year 2021, LRF is accepting the first new research grant in the Jaime Peykoff Follicular Lymphoma Research Initiative, the Follicular Lymphoma Priority Research Grant, as well as applications for its 2022 Early Career Grant programs: the Clinical Investigator Career Development Award (CDA), Postdoctoral Fellowship Grant, and Lymphoma Scientific Research Mentoring Program (LSRMP).
FAQs about our grant programs are listed below. To receive an email notification when future RFPs are released, please click here to subscribe to research grant announcements.
For information about applying for patient aid grants, please visit lymphoma.org/financialsupport.
LRF staff will have limited availability August 28- September 6, 2021 and responses to grant applicant inquiries during this period may be delayed. Please plan accordingly as extensions will not be given due to a delay in response. LRF recommends that inquiries regarding applicant eligibility be submitted no later than August 16 to ensure a timely response.
2022 Grant Applications
Application Period – June 4 – September 8, 2021, 5:00pm EDT
Disease Focus Area Grants (open only to invited applicants)
Early Career Grants
- Clinical Investigator Career Development Award (CDA) RFP
- Postdoctoral Fellowship Grant RFP
- Lymphoma Scientific Research Mentoring Program (LSRMP) RFP
Sample Policy, Terms, and Conditions
NOTE: Lymphoma Research Foundation reserves the right to establish any announcement date and deadline it deems necessary and appropriate for any RFP, and to change deadlines, forms, and guidelines, plus any and all details pertaining to grant availability, rules, eligibility criteria, selection process, etc. All LRF Research Grants are dependent on funding availability.
Research Grant FAQs
Is a Letter of Intent (LOI) required?
While LOI’s are not required for most LRF grants (including all early-career grant programs), the Follicular Lymphoma Priority Research Grant does require an LOI. The LOI period for this grant will be March 15-April 30, 2021.
When is the proposal due?
The submission deadline for all full applications in the 2022 grant cycle – including FL Priority Research Grants that advance past the LOI stage — is 5:00 pm EST on Wednesday, September 8, 2021.
Who is eligible to apply for these grants?
Early career investigator grants are generally open to advanced fellows and junior faculty who are working at a non-profit organization or research institution such as universities, colleges, hospitals, and laboratories in the United States and Canada. The CDA is open to clinical fellows and faculty only; the Postdoctoral Fellowship is open to both clinical and postdoctoral fellows. The LSRMP is open to both clinical and postdoctoral fellows, as well as MD and PhD junior faculty, but specific eligibility varies between the clinical and lab/translational track. Please refer to the individual RFPs for exact eligibility criteria.
Disease Focus Area grants are open to principal investigators who hold an academic faculty appointment of assistant, associate, or full professor or its equivalent, at non-profit organizations or public or private institutions such as universities, colleges, hospitals, and laboratories in the United States and Canada, as long as the project fits the focus area criteria outlined in the RFP. For-profit entities are not eligible to apply for LRF funds. Please refer to the individual RFPs for exact eligibility criteria.
If you are unsure if an investigator or specific project is eligible for a particular Lymphoma Research Foundation grant, please contact email@example.com well in advance of the deadline.
What types of research projects are accepted?
LRF grants seek research projects that focus exclusively on the study of lymphoma and/or chronic lymphocytic leukemia (CLL). Projects which combine the study of lymphoma/CLL with another cancer or hematologic malignancy (including myeloma and other leukemias) will not be accepted. Different mechanisms may require a focus on a specific type of research (for example, the CDA requires a project with a significant clinical component), or a focus on a specific lymphoma subtype or patient population. Database studies, health outcomes research, and/or epidemiological studies, or projects with these components, are welcome where indicated in the RFP. Please review individual RFPs carefully to determine if a project aligns with the eligibility criteria.
If you are unsure if an investigator or project is eligible for a particular grant project, please contact firstname.lastname@example.org well in advance of the deadline.
How much flexibility do I have in the start date of this grant?
For most LRF research grants in the 2022 cycle the earliest available start date is March 1, 2022 and the latest available start date is July 1, 2022. Applicants who cannot start their projects or accept funding until after July 1 should apply in the next cycle.
For LSRMP awards, the RFP specifies the exact dates that should be used for the budget periods, LRF cannot adjust dates for LSRMP awards.
What is the percentage of grant proposals funded by LRF?
Between 2017-2021, the average success rate for applicants to LRF early-career grant programs was as follows:
Clinical Career Development Awards: 38%
Postdoctoral Fellowship Grants: 32%
LSRMP-Clinical Track: 54%
LSRMP-Translational Track: 86%
Please note: The LSRMP-Translational Track is based on one year of applications, 2021. Fl Priority Research Grant success rates cannot currently be calculated as this is the first year the program has been offered.
Do LRF grants include overhead/indirect costs?
Early career grants do not allow overhead or indirect costs, however faculty-level grants such as the FL Priority Research Grant usually allow a set percentage of overhead and indirect costs, which are included in the total award amount. For example, for the FL Priority Research Grant, research expenses plus overhead should total no more than $750,000.
What are the citizenship requirements for applicants?
Eligible applicants must be a citizen of the United States or Canada or hold a visa to work in the United States or Canada. In addition, applicants must be able to commit to remaining at an American or Canadian institution for the duration of the project. *In some cases, Disease Focus Area grants may allow international collaborators if the majority of work is being done at a U.S. or Canadian institution.
Are American/Canadian citizens working at an institution in another country eligible?
No. Applicants to these programs must be based at an institution in the United States or Canada for the duration of the project.
Are proposals with multiple Principal Investigators (PIs) acceptable?
Applications should be filed in the name of one person who will serve as the primary PI for administrative purposes (disbursing funds, filing reports, etc.).
For Disease Focus Area grants, a “co-PI” may be designated under certain circumstances– please see the program RFP for specific guidelines. Early Career Grants (CDA, Fellowship, LSRMP) should not include co-PIs.
Must a hard copy of the entire application be mailed?
No. Applicants are not required to mail a hard copy of any application component. Please note that any required signature and waiver pages must be signed by parties designated in the RFP (for full applications this will include institutional officials) in one of two ways:
- The signature page may now be electronically signed directly through the Proposal Central application (see RFP for details).
- The waiver may either be signed via an electronic signature program such as Adobe Sign or DocuSign, or printed, signed, and scanned to create a PDF. Both versions would then be uploaded into the “Attachments” section of the application.
Note: For electronic signatures, any program that includes a verification mark or code with the electronic signature is acceptable.
Do I have to have an ORCiD to apply for a grant?
In keeping with current NIH policy, LRF requests all applicants to provide ORCiDs at the time of application beginning with the summer 2020 cycle. Please follow the instructions in the “Applicant” screen of the Proposal Central application to link an existing account or create a new one at orcid.org.
ORCiDs will not be required for summer 2020 applications, but LRF strongly encourages applicants to obtain and/or provide their ORCiDs as we anticipate moving to a requirement in future application cycles.
What biosketch format should my key personnel and I use?
Please use the current NIH biosketch format. Postdoctoral Fellowship applicants should note that if they choose to use the fellowship biosketch they are not required to include grades and courses in Section D. All other grant applicants and any mentors, sponsors, or key personnel should use the non-fellowship biosketch template.
What font should I use?
Any legible font 11 points or larger is acceptable.
Are there limits on the number of pages?
Yes, please refer to the RFP for each program for page limits. Please note that where page limits are indicated, proposals which exceed those limits will be disqualified from review.
Is there a required format for my letters of support?
The format of letters of support is left to the discretion of the writer; please refer to each program’s RFP for content requirements. All letters should be submitted on institutional letterhead. In general, support letters should be written by someone familiar with the applicant’s work in general and/or the proposed project specifically.
Postdoctoral Fellowship, CDA, and LSRMP applicants should note that their mentor or sponsor letter should include a detailed description of the applicant’s contribution to the proposed project (any work the applicant individually did to develop the project independently of the sponsor or other colleagues).
Additional letters, uploaded as part of the appendix, may be required to verify support from pharmaceutical partners or other collaborating entities. Review each program’s RFP for details.
Please also note that all anonymized support letters must be uploaded into Proposal Central ahead of the deadline or the application cannot be submitted. Applicants should confirm that their letter writers have received their request email from Proposal Central and are able to log in to the system well in advance of the deadline to avoid issues with their submission.
Is there any specific format for publications?
Publications must be uploaded in PDF format.
How should I upload my assurances (i.e. IRB, IACUC, biohazards)? What if I don’t have approval yet?
If IRB/IACUC/etc. approval is applicable to the project and has been received, in the “Organization Assurances” screen of the Proposal Central application select “approved,” fill in the appropriate certificate numbers, and upload proof of approval as an attachment. Note: applicants only need to upload proof of approval, not the full certificate.
If approval has not yet been received, select “pending” as the response, and upload an attachment noting that approval is pending and the approximate date a decision is expected. Please note that you must demonstrate receipt of the appropriate assurances in order to receive your award, if selected. You will be asked to provide proof of approval after you are notified of your award.
LSRMP applicants will also be asked to indicate any pending or procured assurances on the Cover Sheet template.
Why is proposalCENTRAL asking me to import my Other Research Support from my profile? Do I have to import this info or can I fill it in manually?
proposalCENTRAL allows applicants to store other research support in their individual profile and import it into an application as needed. Follow the directions on the application page to import funding from your profile to the application, or use the indicated buttons to open your profile to add new entries. For technical assistance with this section, contact proposalCENTRAL technical support at email@example.com .
Who conducts the grant review?
Applications will be reviewed by members of LRF’s Scientific Advisory Board (SAB), which is comprised of some of the leaders in the field of lymphoma research, and, where applicable, other researchers with expertise in the specific areas being funded.
Will I have the opportunity to respond to feedback and re-submit my application?
The LRF Scientific Advisory Board may elect to provide feedback to applicants discussed during the final round of review. This feedback will be for the improvement of future grant submissions only; responses and resubmissions during the current grant cycle are not permitted. The SAB’s decision is final.
Please note, if an applicant chooses to revise and resubmit a project in a future application cycle, they should indicate the project is a resubmission on the appropriate question in the application system. This will link their new application to the previous one and allow the review committee to assess the revisions that have been made.
When will I find out if my LOI has advanced/if I have been selected for an award?
FL Priority Research Grant LOI applicants will be notified if they are invited to submit a full application by June 4, 2021.
All applicants who submit a full application in the 2022 cycle will be notified in writing by December 22, 2021.
I am an early-career grant applicant, can I have a mentor/sponsor who is not at my home institution?
Your primary mentor/sponsor should be based at your home institution, however, you are welcome to have associate mentors or sponsors at other institutions if their expertise will be particularly relevant to your proposed project. Please note if you have more than one mentor/sponsor, a biosketch should be submitted for each person, and each person should submit separate recommendation letters – however the associate mentor/sponsor letters may count towards your additional required recommendation letters.
Must my CDA project involve clinical research?
Yes– the focus of the training is to prepare clinicians to design and administer clinical studies in lymphoma and to take on the primary responsibilities for clinical trial design, protocol writing, Institutional Review Board (IRB) submission, and publication. Proposals must involve clinical observation of human subjects and may include study or development of new diagnostic, methods, therapies, and/or outcome measurements directed to patients with lymphoma. Studies or proposals that are exclusively laboratory based are not appropriate for this program.
Are non-clinicians eligible to apply for the CDA?
No– applicants must be licensed clinical physicians in one of the ACGME accredited specialties and be working at a clinical research institution in the United States or Canada for the duration of the grant award period.
What time commitment is required for the CDA?
The Clinical Investigator must spend a minimum of 35 to 50 percent of his/her time in research. This time should be free of major patient care, teaching or administrative responsibilities.
What is the Peykoff Follicular Lymphoma Initiative?
LRF will be funding a minimum of two CDA awards in the 2022 cycle for an exemplary research project focused exclusively on adult follicular lymphoma. This award is being offered in addition to the funding already reserved for LRF’s CDA awards, which will be awarded to the strongest applications regardless of subtype.
What is the LRF Health Equity Initiative?
LRF will be funding a minimum of one CDA in the 2022 cycle that either focuses on health equity issues in lymphoma and CLL, or is initiated by PIs from underrepresented groups in the lymphoma and CLL research fields. These groups include: American Indians or Alaska Natives, Blacks or African Americans, Asian Americans, Hispanics or Latinos, Native Hawaiians or other Pacific Islanders, Asian Canadians, African Canadians, Inuit, First Nation Peoples, and Women. Applicants must also be a citizen or permanent resident of the United States or Canada and meet all other eligibility criteria for the CDA. This award is being offered in addition to the funding already reserved for LRF’s Career Development Awards; applicants who indicate they are eligible for the Health Equity Initiative funding will also be eligible for CDAs funded through other sources.
What does “one mentor per applicant” mean?
Each CDA applicant should have a primary mentor that is not designated as primary mentor for another LRF CDA applicant in the same cycle. The primary mentor should be in a faculty role (preferably senior faculty) in the department where the applicant will be performing the research for their CDA project. If there are multiple CDA applicants with the same primary mentor, LRF will request that the mentor designate which application to accept for review.
Please note that a CDA applicant may have a primary mentor who has served as mentor for a CDA applicant in a past cycle (even if that applicant is currently an active CDA grantee). A CDA applicant may also have a primary mentor who is serving as primary mentor for a Postdoctoral Fellowship and/or LSRMP applicant in the current cycle.
Must my Fellowship project involve clinical research?
No, both laboratory and clinic based projects are acceptable, but the results and conclusions must be clearly relevant to the treatment, diagnosis or prevention of Hodgkin and/or non-Hodgkin lymphoma. Areas of research may include, but are not limited to, etiology, immunology, genetics, therapies and transplantation. Historically, successful applications in this program have focused on basic, translational, and epidemiological research.
I’m not a faculty member yet, but I will be starting a position this fall. Can I apply for a Fellowship grant?
No. Postdoctoral Fellowships are not open to applicants who move into faculty positions prior to the start date indicated on their application budget. Applicants receiving an award may move into a faculty position during the period of the grant.
Junior faculty members in clinical research may be eligible to apply to the CDA or LSRMP, and Instructor level PhDs may be also eligible for the LSRMP; see those RFPs for details.
I have a PhD, and I’m doing postdoctoral work, not an ACGME fellowship program – what does the “two years” requirement mean for me?
If you are a PhD not participating in an ACGME fellowship program, the two year requirement does not apply to you. You may apply for the fellowship at any time in the first five years (60 months) of your postdoctoral work, as long as you will not be beyond five years as of March 1, 2022.
I have an MD and I’m a clinical fellow – do I have to meet both the two year minimum and five year maximum requirement?
Yes– clinical fellows must have completed at least two years (24 months) of fellowship work and no more than five years (60 months) of fellowship work as of March 1, 2022 to apply for a Postdoctoral Fellowship. If you are beyond the five year limit, you may be eligible for either the CDA or LSRMP programs – see those RFPs for details.
What time commitment is required for a Fellowship?
The Fellow must spend a minimum of 80 percent of his/her time in research without major patient care, teaching, or administrative responsibilities except as such responsibilities relate directly to a pre-clinical or clinical lymphoma research project.
What does “one sponsor per applicant” mean?
What does “one sponsor per applicant” mean?
Each Postdoctoral Fellowship grant applicant should have a primary sponsor that is not designated as primary sponsor for another LRF Fellowship applicant in the same cycle. The primary sponsor should be in a faculty role (preferably senior faculty) in the lab (for basic or translational projects) or department (for clinical projects) where the applicant will be performing the research for their Postdoctoral Fellowship project. If there are multiple Fellowship applicants with the same primary sponsor, LRF will request that the sponsor designate which application to accept for review.
Please note that a Fellowship applicant may have a primary sponsor who has served as sponsor for a Fellowship applicant in a past cycle (even if that applicant is currently an active Fellowship grantee). A Fellowship applicant may also have a primary sponsor who is serving as primary sponsor for a CDA and/or LSRMP applicant in the current cycle.
What is the Lymphoma Research Foundation Health Equity Initiative?
LRF will be funding a minimum of one Postdoctoral Fellowship Grant in the 2022 cycle initiated by PIs from underrepresented groups in the lymphoma and CLL research fields. These groups include: American Indians or Alaska Natives, Blacks or African Americans, Asian Americans, Hispanics or Latinos, Native Hawaiians or other Pacific Islanders, African Canadians, Asian Canadians, Inuit, First Nation Peoples, and Women. Applicants must also be a citizen or permanent resident of the United States or Canada and meet all other eligibility criteria for the Fellowship Grant. This award is being offered in addition to the funding already reserved for LRF’s Postdoctoral Fellowship Grants; applicants who indicate they are eligible for the Health Equity Initiative funding will also be considered for Postdoctoral Fellowship Grants funded through other sources.
What is the Peykoff Follicular Lymphoma Initiative?
LRF will be funding a minimum of one fellowship grant in the 2022 cycle for a project focused exclusively on research in adult follicular lymphoma. Funding has been reserved for three additional fellowship grants for projects that are relevant to the priority areas in the LRF Follicular Lymphoma Initiative Discovery Meeting white paper [https://lymphoma.org/wp-content/uploads/2021/04/6712-LRF-FL-White-Paper-v.4-11_25.pdf]. Eligible projects will include at least one research aim relevant to the list of priority areas in the white paper, including, but not limited to, the biology of transformation and the identification of predictive biomarkers or other prognostic factors for first-line, relapsed, and transformed lymphoma patients. These projects do not have to study FL exclusively, although the use of FL tissue and/or patients in some proportion are encouraged.
These awards are offered in addition to the funding already reserved for the Postdoctoral Fellowship Grants; applicants who are eligible for Follicular Initiative funding will also be considered for Postdoctoral Fellowship Grants funded through other sources.
How does the LSRMP differ from the Lymphoma Clinical Research Mentoring Program (LCRMP) LRF sponsored in previous years?
The Lymphoma Scientific Research Mentoring Program (LSRMP) combines the existing LCRMP curriculum and grant structure with an additional cohort for MD and PhD early career researchers who are preparing for careers focused on laboratory and translational research. Participants in both tracks will attend the LSRMP Workshop and follow up programs, which will feature both curricula tailored specifically to their chosen research track and collaborative opportunities for laboratory/translational and clinical researchers to work together and learn from each other.
Should I apply to the clinical track or the laboratory/translational track?
Each LSRMP track has its own application in Proposal Central. Applicants should choose the track most appropriate for their application and apply there – applicants may not apply to both tracks in the same application cycle. On the title page of the Proposal Central application, applicants may indicate if they are willing to be considered in either track based on the review committee’s assessment. Please note that applicant eligibility varies between tracks and applicants can only be moved between tracks if they meet both tracks’ eligibility criteria.
Non-clinicians (postdoctoral fellows and PhD junior faculty) are only eligible to apply to the laboratory/translational track. MD junior faculty and clinical fellows may apply to either track as long as they meet the eligibility criteria; however please keep in mind that applicants will be assessed on the appropriateness of their proposed project and Career Development Plan to the track they have chosen.
Please review the full criteria for each track located in the RFP, particularly “Research Objectives and Evaluative Factors” on page 5 as well as the “Applicant Eligibility” section for each track (pages 6 and 7). Questions about a project’s suitability for either track should be directed to firstname.lastname@example.org well in advance of the deadline.
How are the LSRMP eligibility requirements calculated?
For all LSRMP eligibility requirements, the applicant must have met any minimum limits and not exceeded any maximum limits by March 1, 2022. Applicants should review the RFP for eligibility for their chosen track as requirements vary depending on track and applicant job title.
Applicants who are unsure whether they meet the eligibility requirements for either track are welcome to email email@example.com for assistance well in advance of the deadline.
What time commitment is required for the LSRMP?
Selected applicants must be able to attend and participate in all parts of the program including the workshop from March 7 through March 11, 2022 in Scottsdale, AZ, the follow-up meetings in Fall 2022 and 2023, and LRF required communication, reporting and evaluation.
Please note where in person programming is currently indicated, LRF will monitor the recommendations from local and federal health officials and implement alternate plans as necessary.
Is my Mentor required to attend the workshop?
No, Mentors are expected to provide support and guidance to the Applicant while he/she is at their home institution and assist with the execution of the Applicant’s research project. They will not be asked to attend the March workshop or follow up programs.
If applicants from the same institution apply, can they both be chosen?
Only one individual per institution will be accepted to a given track. This means an institution could have both a clinical track and a translational track participant, however, if there are multiple applicants from one institution in the same track, the review committee will only select one of these for the program.
I am a fellow anticipating moving into a faculty position soon. How do I address this in my application?
Please see the cover sheet and instructions for the Research Proposal in the RFP, which note where you should address any anticipated changes of rank or institution, and its estimated impact on your research proposal.
For laboratory/translational track applicants, please note that applicants who move into an Assistant Professor position prior to the March 2022 workshop are not eligible to participate in the program. Applicants selected for the program may move into an Assistant Professor position following the workshop and remain in the program.
I’ve already participated in a different mentorship program with ASH (or any other organization). May I apply for the LRF program?
Yes. Applicants who have completed ASH’s CRTI program, the EHA-ASH TRTH program or another mentorship program may apply for LRF’s program. However, you may not participate in another competitively applied for mentorship during the period of the LRF program (March 2022 through October 2024).
What is the Kanti Rai, MD Chronic Lymphocytic Leukemia Scholar Award?
LRF will be funding a minimum of one LRF Scholar in the 2022 cycle for a research project focused exclusively on chronic lymphocytic leukemia/small lymphocytic lymphoma. Clinical and translational track applicants are eligible for this award. This award is being offered in addition to the funding already reserved for LRF’s LSRMP program, which will be awarded to the strongest applications regardless of subtype.
What is the Jamie Peykoff Follicular Lymphoma Initiative?
Established in 2020 through the generosity of the Peykoff Family and Niagara Cares, the $10 million Initiative is poised to transform the follicular lymphoma treatment landscape for patients by harnessing the Lymphoma Research Foundation’s (LRF) unique resources, convening the world’s experts in follicular lymphoma research and patient care, and driving direct investment in biomedical research.
What type of research grants will be funded?
Currently, the Initiative’s research funding is composed of the Follicular Lymphoma (FL) Priority Research Grant for faculty-level investigators (first offered for the 2022 cycle), as well as designated awards for exemplary follicular lymphoma-focused projects in all three of the Foundation’s early career grant programs. The early career grant programs consist of Clinical Investigator Career Development Awards (CDA), Postdoctoral Fellowship Grants and the Lymphoma Scientific Mentoring Program (LSRMP). This approach will allow the Initiative to fund a wide variety of research projects as well as investigators at all levels of their careers.
I am early career faculty who is eligible for an LRF early career grant - may I apply to the FL Priority Research Grant as well?
No. If you are eligible for any of LRF’s early career grant programs (CDA, Fellowship or the LSRMP) you may not be a PI or co-PI on an FL Priority Research Grant. You may be key personnel on an FL Priority Research Grant application if you are in a non-PI role.
Note that if you have previously received an LRF CDA and you will have passed the end date of that grant prior to March 1, 2022, you may apply for an FL Priority Research Grant, as CDA recipients may not receive a second CDA.
When will RFPs for the early career grants be available and where may I find this information?
The RFPs for all LRF early career grants will be released on June 4, 2021 and will be posted on this webpage. To ensure that you receive the email announcement when these RFPs are available, select “Sign up: Grant Announcements” from the side menu.
I am applying to an early career research grant program, and my mentor is applying to an FL Priority Research Grant. May we use the same project for our applications?
No. While early career grant proposals can address a topic or research question that is related to a Priority Research Grant proposal, they should be capable of being executed independently of any other LRF application.
Which signatures are required for the FL Priority Research Grant LOI?
For the LOI stage of the FL Priority Research Grant, the PI and any designated co-PIs will need to log in to Proposal Central to sign the signature page electronically. Institutional official signatures will not be required until the full application stage (although please note a support letter from the institution is required with the LOI).
What requirements exist for multi-institution submissions for the FL Priority Research Grant?
The FL Priority Research Grant encourages collaboration, which may include the participation of multiple research institutions on a single application. Please note all institutions on a project must be eligible for LRF funding per the RFP. For multi-institution projects, only one PI may be designated per institution, however, a primary PI should serve as the applicant, with the others designated as co-PI. If funded, the primary PI and their institution will be responsible for the administration of the award, including submitting scientific and financial progress reports and disbursing funds to collaborating institutions.
Please note that the naming of co-PIs is optional, but that each institution on a multi-institution grant should designate at least a non-PI Site Lead (co-PIs will automatically be considered Site Leads for their site). Site Leads may be any faculty-level researcher with an MD, PhD, or equivalent degree at their indicated institution, and do not have to meet other PI eligibility requirements. Also note that collaborators outside of the U.S. and Canada may not be named a co-PI, but can be Site Lead or other key personnel on an application if the bulk of the research project is being done in the U.S. or Canada.
Please note that at the full application stage, multi-institution applications should also include a project leadership plan that explains the roles of the PI, co-PIs, and site leads in the management of the project including a process for making decisions on scientific direction and a plan for resolving conflicts. See the RFP for instructions on where to include this within the research proposal.
My FL Priority Research Grant project is based only at my institution. May I name a co-PI?
Yes, please refer to the RFP and follow all guidelines for Multiple co-PI projects. Please be aware that all co-PIs will need to log in to Proposal Central and sign the LOI or application in the “signature page” section prior to submission in each stage.
Can my institution submit multiple applications to the FL Priority Research Grant?
Yes. There is no limit on the number of applications an institution may submit to the FL Priority Research Grant. However, please note that anyone designated a PI, co-PI, or Site Lead on a FL Priority Research Grant application cannot serve as PI, co-PI, Site Lead or key personnel on another FL Priority Research Grant application in the same cycle.
Can I make changes to my project in the full application stage?
Yes, please see the RFP for where to indicate any changes to the project aims, scope, or personnel from the LOI in the research proposal, along with a rationale for these changes. Please note that the review committee reserves the right to decide that a project with significant changes from the LOI stage is no longer the approved project and cannot be reviewed in this cycle.